BRPI0416853A - pirazolila e imidazolila pirimidinas - Google Patents

pirazolila e imidazolila pirimidinas

Info

Publication number
BRPI0416853A
BRPI0416853A BRPI0416853-4A BRPI0416853A BRPI0416853A BR PI0416853 A BRPI0416853 A BR PI0416853A BR PI0416853 A BRPI0416853 A BR PI0416853A BR PI0416853 A BRPI0416853 A BR PI0416853A
Authority
BR
Brazil
Prior art keywords
pyrazolyl
pyrimidines
imidazolyl pyrimidines
compounds
formula
Prior art date
Application number
BRPI0416853-4A
Other languages
English (en)
Inventor
Alam Jahangir
Counde O'yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0416853A publication Critical patent/BRPI0416853A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"PIRAZOLILA E IMIDAZOLILA PIRIMIDINAS". A presente invenção refere-se a compostos da fórmula (I), e seus sais farmaceuticamente aceitáveis, onde X, Y, Z e R¬ 1¬ são como aqui definidos. A invenção também provê métodos para a preparo, composições compreendendo, e métodos para uso de compostos de fórmula I para preparo de medicamentos.
BRPI0416853-4A 2003-11-24 2004-11-16 pirazolila e imidazolila pirimidinas BRPI0416853A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52454703P 2003-11-24 2003-11-24
PCT/EP2004/012985 WO2005054231A1 (en) 2003-11-24 2004-11-16 Pyrazolyl and imidazolyl pyrimidines

Publications (1)

Publication Number Publication Date
BRPI0416853A true BRPI0416853A (pt) 2007-02-13

Family

ID=34652269

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416853-4A BRPI0416853A (pt) 2003-11-24 2004-11-16 pirazolila e imidazolila pirimidinas

Country Status (11)

Country Link
US (1) US7414059B2 (pt)
EP (1) EP1689740A1 (pt)
JP (1) JP2007512275A (pt)
KR (1) KR100861515B1 (pt)
CN (1) CN100554264C (pt)
AU (1) AU2004295050A1 (pt)
BR (1) BRPI0416853A (pt)
CA (1) CA2545992A1 (pt)
MX (1) MXPA06005735A (pt)
RU (1) RU2377241C2 (pt)
WO (1) WO2005054231A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2007041358A2 (en) * 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR102703498B1 (ko) 2015-09-23 2024-09-04 얀센 파마슈티카 엔브이 신규 화합물
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
AU2018390994B2 (en) 2017-12-22 2023-11-16 Mirage 3.4D Pty Ltd Camera projection technique system and method
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
NZ524100A (en) * 2000-08-08 2005-01-28 Ortho Mcneil Pharm Inc 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
AU9458401A (en) * 2000-09-20 2002-04-02 Ortho Mcneil Pharm Inc Pyrazine derivatives as modulators of tyrosine kinases
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7205306B2 (en) * 2001-05-14 2007-04-17 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US6887875B2 (en) * 2001-06-12 2005-05-03 Neurogen Corporation 2,5-diarypyrimidine compounds
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2004212421B2 (en) * 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1651619A1 (en) * 2003-07-15 2006-05-03 Neurogen Corporation Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Also Published As

Publication number Publication date
AU2004295050A1 (en) 2005-06-16
WO2005054231A1 (en) 2005-06-16
KR100861515B1 (ko) 2008-10-02
CN1882574A (zh) 2006-12-20
US7414059B2 (en) 2008-08-19
RU2006122416A (ru) 2008-01-10
MXPA06005735A (es) 2006-08-17
EP1689740A1 (en) 2006-08-16
RU2377241C2 (ru) 2009-12-27
CA2545992A1 (en) 2005-06-16
US20050113382A1 (en) 2005-05-26
KR20060088564A (ko) 2006-08-04
CN100554264C (zh) 2009-10-28
JP2007512275A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
BR0316375A (pt) Diazinopirimidinas
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0210507A (pt) Azaindóis
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
BR0316470A (pt) Derivados de 3-amino-piperadina e métodos de preparação
DK1737459T3 (da) Imidazopyridin og imidazopyrimidinderivater som antibakterielle midler
SE0400284D0 (sv) Novel compounds
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
UA94065C2 (en) Dihydropseudoerythromycin derivatives
NO20085087L (no) Nye heterocykliske forbindelser
BR0315302A (pt) Benzoxazinonas substituìdas e seus usos
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2006116733A3 (en) Protein kinase inhibitors
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
BR0212069A (pt) Agentes antidiabéticos orais
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.